Produção Nacional
Revisado por pares
Characteristics associated with COVID-19 vaccine hesitancy: A nationwide survey of 1000 patients with immune-mediated inflammatory diseases
2021; Elsevier BV; Volume: 39; Issue: 44 Linguagem: Inglês
10.1016/j.vaccine.2021.09.057
ISSN1873-2518
AutoresRodrigo Poubel Vieira de Rezende, Alessandra Sousa Braz, Maria Fernanda Brandão de Resende Guimarães, Sandra Lúcia Euzébio Ribeiro, Rejane Maria Rodrigues de Abreu Vieira, Blanca Elena Ríos Gomes Bica, Vítor Alves Cruz, Ketty Lysie Libardi Lira Machado, Joana Starling de Carvalho, Odirlei André Monticielo, Lilian David de Azevêdo Valadares, Kátia Lino, ANNA CAROLINA F M GOMES TAVARES, Adriana María Kakehasi, Edgard Torres dos Reis Neto, Ana Karla Guedes de Melo, Gilda Aparecida Ferreira, Viviane Angelina de Souza, Gecilmara Salviato Pileggi, Marcelo M. Pinheiro,
Tópico(s)Heparin-Induced Thrombocytopenia and Thrombosis
ResumoTo identify potential predictors of COVID-19 vaccine hesitancy (C19-VH) in adults with immune-mediated inflammatory diseases (IMID). A total of 1000 IMID patients were enrolled in this web-based cross-sectional study. A standardised and self-administered survey was designed by members of the Brazilian Society of Rheumatology Steering Committee for Infectious and Endemic diseases and distributed to IMID patients spread across Brazil. Of the 908 (90.8%) respondents eligible for analysis, 744 (81.9%) were willing to get vaccinated against COVID-19. In our multivariable logistic regression model, concurrent malignancy, fibromyalgia, hydroxychloroquine use, and recent corticosteroid pulse therapy were independently associated with higher odds of C19-VH. The short duration of COVID-19 vaccine clinical trials was the main reason for C19-VH. We identified novel characteristics potentially associated with C19-VH among adults with IMID. Greater awareness on the safety and efficacy of COVID-19 vaccines is needed for both IMID patients and attending physicians.
Referência(s)